Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 3 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Player Avatar TMFCop (90.08) Submitted: 1/21/2012 8:42:09 AM : Outperform Start Price: $13.23 ELN Score: +7.64

New labeling and new tests for PML from Quest Diagnostics should open up even more markets -- and sales -- to Tysabri.

Featured Broker Partners


Advertisement